Exome Asset Management’s Cytokinetics CYTK Stock Holding History

Exome Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.12M	Sell	60,056 -43,662	-42%	-$3.14M	3.16%	9
2026 Q1	$6.84M	Sell	103,718 -21,031	-17%	-$1.34M	3.54%	7
2025 Q4	$7.93M	Sell	124,749 -17,668	-12%	-$1.1M	3.79%	6
2025 Q3	$7.83M	Buy	142,417 +26,600	+23%	+$1.1M	4.74%	2
2025 Q2	$3.83M	Buy	115,817 +12,334	+12%	+$429K	2.85%	9
2025 Q1	$4.16M	Buy	103,483 +37,600	+57%	+$1.73M	3.7%	5
2024 Q4	$3.1M	Buy	65,883 +7,300	+12%	+$379K	2.33%	19
2024 Q3	$3.09M	Buy	+58,583	New	+$3.27M	2.09%	19
2024 Q2	–	Sell	-26,008	Closed	-$1.82M	–	58
2024 Q1	$1.82M	Sell	26,008 -8,900	-25%	-$688K	1.56%	25
2023 Q4	$2.91M	Buy	+34,908	New	+$1.26M	2.88%	11

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exome Asset Management's CYTK Position: Q2 2026 in Review

Exome Asset Management reduced its Cytokinetics (CYTK) stake by 42% in Q2 2026, selling an estimated $3.14M and leaving 60,056 shares worth $5.12M. The position accounts for 3.16% of the portfolio, ranked #9.

Exome Asset Management first reported a position in CYTK in Q4 2023 and has held it in 10 quarters since. The position peaked at $7.93M in Q4 2025. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Exome Asset Management held 60,056 shares of Cytokinetics worth $5.12M as of Q2 2026.
Exome Asset Management sold 43,662 Cytokinetics shares in Q2 2026, an estimated $3.14M.
Cytokinetics made up 3.16% of Exome Asset Management's portfolio in Q2 2026, its #9 holding.
Exome Asset Management first reported a position in Cytokinetics in Q4 2023 and has held it in 10 quarters since.
Exome Asset Management's Cytokinetics position peaked at $7.93M in Q4 2025.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.